AEON Biopharma Inc. is a clinical-stage biopharmaceutical company. It focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions. AEON Biopharma Inc., formerly known as Priveterra Acquisition Corp., is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-39.22M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -763.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.99 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.99 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $-4.55 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.44 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.90 |
| Diluted Earnings per Share (Trailing 12 Months) | $-5.00 |
| Exchange | NYSEMKT |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.30M |
| Free Float | 22.93M |
| Market Capitalization | $18.51M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 0.61 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 22.78% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |